4.3 Article

Efficacy and safety of etanercept in psoriasis and psoriatic arthritis in the PRESTA study: analysis in patients from Central and Eastern Europe

期刊

JOURNAL OF DERMATOLOGICAL TREATMENT
卷 29, 期 1, 页码 8-12

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1080/09546634.2017.1329509

关键词

Efficacy; etanercept; psoriatic arthritis; safety

资金

  1. Pfizer

向作者/读者索取更多资源

Background: Data are limited on the effectiveness of anti-TNF and other biologics on psoriatric arthritis (PsA) in Central and Eastern Europe (CEE). The objective of this analysis was to evaluate the efficacy of etanercept (ETN) in PsA patients from CEE.Methods: In PRESTA, patients were randomized to receive ETN 50mg BIW or 50mg QW for 12 weeks (double-blind phase) and ETN 50mg QW for 12 additional weeks (open label). In this analysis, only patients from Czech Republic, Hungary, Poland and Serbia were included. The primary efficacy variable was the proportion of subjects achieving a physician global assessment (PGA) of psoriasis status: clear or almost clear at week 12.Results: In the 307 patients, 54% BIW/QW compared with 40% (QW/QW) (p=.02), achieved clear/almost clear for PGA of psoriasis at week 12 increasing, to 68% and 60%, respectively (p=.134) by week 24. Mean improvement from baseline in PASI were 59% versus 49% (p=.005) at week 6 and 87% versus 81% (p<.05) at week 24, for the BIW/QW and QW/QW groups, respectively. ETN was well tolerated in both groups over 24weeks.Conclusions: Both dose regimens of ETN provided significant improvements in efficacy in PsA treatment and were well tolerated.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据